youtube_live
Q4 2026 earnings • released • EPS miss -1.20% • Revenue miss -39.67%
See resultschevron_right
ARWR:NASDAQ
Arrowhead Pharmaceuticals Inc
$47.78
arrow_upward
+1.34%(+0.63) 1D
$47.30
arrow_downward
-1.00% (-0.48)bedtimeAfter hours
Closed: Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ARWR...
Open
$47.68
High
$48.29
Low
$44.52
Mkt. cap
6.75B
Avg. vol.
1.98M
Volume
3.11M
52-wk high
$95.49
52-wk low
$37.06
EPS
-$2.24
Beta
1.34
Shares outstanding
141.25M
No. of employees
711
Open
$47.68
High
$48.29
Low
$44.52
Mkt. cap
6.75B
Avg. vol.
1.98M
Volume
3.11M
52-wk high
$95.49
52-wk low
$37.06
EPS
-$2.24
Beta
1.34
Shares outstanding
141.25M
No. of employees
711
News stories
From web sources and news partners
Seeking Alpha
·
14 hours ago
Arrowhead FY2026 Earnings Analysis: Pricey R&D Must Deliver As Market Turns On RNAi
BioSpace
·
14 hours ago
Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
Investing.com
·
16 hours ago
Stifel cuts Arrowhead Pharma stock price target on Tryngolza launch
GuruFocus
·
1 day ago
ARWR SWOT Analysis: Key Insights from 10-K Filing
Profile
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. Wikipedia
About Arrowhead Pharmaceuticals Inc
CEOChristopher Richard Anzalone
Employees711
FoundedJan 1, 2004
HeadquartersPasadena, California, United States
SectorHealth Care
IndustryBiotechnology
Websitearrowheadpharma.com